Plerixafor (AMD3100), a CXCR4 antagonist, inhibits the BM-mediated tumor vasculature in ES by reducing PDGFRβ expression through the disruption of the SDF-1α/CXCR4 axis (Hamdan et al., 2014). This evidence concerns the gene CXCL12 and neoplasm.